Profile

DIMITRA KANALOUPITI

MEDICAL ONCOLOGIST

DIRECTOR-4TH ONCOLOGY CLINIC
  1. General
  • Education & Academic Titles
    • Certification in Medical Oncology by the American Board of Internal Medicine (ABIM), U.S.A
    • Certification in Hematology by the ABIM, U.S.A
    • Certification in Internal Medicine by the ABIM, U.S.A
    • Medical Oncology/Hematology Fellowship, Advocate Lutheran General Hospital (ALGH), Park Ridge/Chicago, U.S.A
    • Internal Medicine Residency, Rush St. Luke’s Hospital/Rush University, Chicago, U.S.A
    • Doctor of Medicine/Medical Degree, Rush Medical College/Rush University, Chicago, U.S.A
    • Bachelor of Science in Biological Sciences/Biology (Magna cum Laude), Loyola University of Chicago, Chicago, U.S.A
  • Professional Experience
    • Attending/Consultant in Medical Oncology/Hematology, Advocate Medical Group, Advocate Lutheran General Hospital (ALGH), Park Ridge/Chicago, USA
    • Assistant Director, 1st Oncology Clinic, Metropolitan Hospital, Athens, Greece
    • Physician Coordinator of Supportive Care Program, 1st Oncology Clinic, Metropolitan Hospital, Athens, Greece
  • Clinical Interests
    • Diagnosis and treatment of all solid tumors
    • Specialized in Breast cancer, Gynecological cancer and Melanoma
    • Supportive and Palliative Care
    • Survivorship
  • Awards & Distinctions
    • Humanitarian Award (Melanoma Research Foundation), Advocate Lutheran General Hospital Physicians, 5th Annual Chicago Gala, U.S.A
    • Cancer Expert Now (CEN) Global Expert Panelist
    • “Fellow of the Year”, Department of Medicine, ALGH, Chicagο, U.S.A
    • Alpha Sigma Nu (ΑΣΝ) National Honor Society
    • Golden Key National Honor Society
    • Phi Beta Kappa (ΦΒΚ) Honor Society
    • Magna Cum Laude Distinction
    • Dean’s List
    • Presidential Scholarship
  • Publications
    • “Acute Myeloid Leukemia with t(4;12)(q12;p13) treated with an Allogeneic Stem Cell Transplant: A case report and review of the literature”. Leukemia Research Reports, 2018 May; 9:76-78. Hancock C, Kanaloupitis D, et al.
    • “Safety and efficacy of concurrent administration of influenza vaccine in patients undergoing anti-PD-1 immunotherapy”. Journal of Clinical Oncology 35, 2017 (suppl; abstr e14607). Kanaloupitis D, Chandran A, et al.
    • “The Dying Patient”. I Drasis mas. 2011 Jan. Kanaloupiti D, Michalakopoulou P.
    • “Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer”. Lancet Oncology. 2008 Oct; 9(10): 962-972. Cited in PubMed; PMID: 18804418. Linardou H, Dahabreh IJ, Kanaloupiti D, et al.
    • “Predisposing factors for critical illness polyneuromyopathy in a multidisciplinary intensive care unit”. Acta Neurol Scandinavica. 2008 Sep; 118(3): 175-181. Cited in PubMed; PMID: 18355395. Nanas S, Kritikos K, Angelopoulos E, Siafaka A, Tsikriki S, Poriazi M, Kanaloupiti D, et al.
    • “Gastrointestinal solitary metastases from squamous cell lung cancer”. Lung Cancer. 2007 Feb; 55(2): 251-252. Cited In PubMed; PMID: 17113186. Karamouzis MV, Linardou H, Papadopoulos G, Bousboukea E, Kanaloupiti D., et al.
    • Propofol-induced hyperamylasaemia in a general intensive care unit”. Anaesth Intensive Care. 2007 Dec; 35(6): 920-923. Nanas S, Angelopoulos E, Tsikriki S, Kritikos K, Voutsinas E, Zervakis D, Kanaloupiti D, et al.
  • Membership in Societies and Editorial Boards
    • American Society of Clinical Oncology (ASCO)
    • Hellenic Society of Medical Oncology (HeSMO)
    • Cancer Expert Now – Global Expert Panelist
    • Mediterranean Multidisciplinary Oncology Forum (ΜΜOF)
    • Medical Society of Athens
    • Multidisciplinary Breast Tumor Board, Advocate Lutheran General Hospital (ALGH), U.S.A
    • Multidisciplinary Gynecologic Oncology Tumor Board, ALGH, U.S.A
    • Melanoma Clinic, ALGH, U.S.A
  • Research
    • “A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects with Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta® (pegfilgrastim) Onpro® kit or Other Physician Choice Options for Prophylaxis of FN (Amgen 20170758)”. Site #1815.
    • “Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)”. Site #0025
    • “Pattern of use and safety/effectiveness of Nivolumab in routine oncology practice”. Study No. CA209234
    • “Safety and Efficacy of Concurrent Administration of Influenza Vaccine in Patients Undergoing Anti-PD-1 Immunotherapy”. IRB No. 6443.
    • “Incidence of Bone Fracture Occurrence and Evaluation of Pain Control in Cancer Patients with Bone Metastases Treated with Zolendronic Acid Monthly Intravenous Infusion: An Epidemiologic/ Observation Study”.